533138 Stock Overview Engages in the manufacture and sale of agrochemical active ingredients and pharmaceutical intermediates in India. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Astec LifeSciences Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Astec LifeSciences Historical stock prices Current Share Price ₹1,079.00 52 Week High ₹1,487.65 52 Week Low ₹826.15 Beta 0.29 1 Month Change 1.52% 3 Month Change -12.51% 1 Year Change -2.19% 3 Year Change -28.79% 5 Year Change 148.27% Change since IPO 1,186.05%
Recent News & Updates
Astec Lifesciences Limited Announces Appointment of Arijit Mukherjee as the Manager Dec 15
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Oct 26
Astec Lifesciences Limited Announces Resignation of Brahma Nand Vyas as an Independent Director Oct 04
Astec Lifesciences Limited Announces Resignation of Anurag Roy as Chief Executive Officer, Effective October 25, 2024 Sep 23
Price target decreased by 14% to ₹1,090 Sep 23 Astec Lifesciences Limited Announces Resignation of Anurag Roy as Chief Executive Officer, Effective October 25, 2024 See more updates
Astec Lifesciences Limited Announces Appointment of Arijit Mukherjee as the Manager Dec 15
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Oct 26
Astec Lifesciences Limited Announces Resignation of Brahma Nand Vyas as an Independent Director Oct 04
Astec Lifesciences Limited Announces Resignation of Anurag Roy as Chief Executive Officer, Effective October 25, 2024 Sep 23
Price target decreased by 14% to ₹1,090 Sep 23 Astec Lifesciences Limited Announces Resignation of Anurag Roy as Chief Executive Officer, Effective October 25, 2024
Insufficient new directors Aug 01
Astec LifeSciences Limited to Report Q1, 2025 Results on Jul 29, 2024 Jul 18
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Jul 08 Astec LifeSciences Limited, Annual General Meeting, Jul 29, 2024
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 03
Astec LifeSciences Limited to Report Q4, 2024 Results on May 02, 2024 Apr 26
Price target decreased by 14% to ₹1,108 Apr 14
Price target decreased by 9.3% to ₹1,205 Jan 28
Third quarter 2024 earnings released: ₹12.41 loss per share (vs ₹0.43 profit in 3Q 2023) Jan 27
Astec LifeSciences Limited to Report Q3, 2024 Results on Jan 25, 2024 Jan 13
Second quarter 2024 earnings released: ₹6.85 loss per share (vs ₹9.34 profit in 2Q 2023) Oct 29
Astec LifeSciences Limited to Report Q2, 2024 Results on Oct 27, 2023 Oct 11
Astec LifeSciences Limited Declares Final Dividend for the Financial Year Ended March 31, 2023 Jul 29
Astec LifeSciences Limited to Report Q1, 2024 Results on Jul 27, 2023 Jul 23
Upcoming dividend of ₹1.50 per share at 0.1% yield Jul 14
Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022) Jul 08
Non-Executive Non-Independent Director recently sold ₹4.8m worth of stock Jun 10
Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable by August 1, 2023 May 04
Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022) May 03
Investor sentiment improves as stock rises 26% Apr 04
Third quarter 2023 earnings released: EPS: ₹0.43 (vs ₹12.63 in 3Q 2022) Jan 31
Astec LifeSciences Limited to Report Q3, 2023 Results on Jan 30, 2023 Jan 12
Price target decreased to ₹1,923 Jan 05
High number of new directors Nov 16
Second quarter 2023 earnings released: EPS: ₹9.34 (vs ₹4.63 in 2Q 2022) Nov 03
Astec Lifesciences Limited Announces Appointment of Mr. Madhur Gundecha as the Chief Financial Officer Oct 29
Astec LifeSciences Limited to Report Q2, 2023 Results on Oct 28, 2022 Oct 21
Investor sentiment improved over the past week Oct 17
Astec LifeSciences Limited Announces the Resignation of Saurav Bhala as Chief Financial Officer Oct 01
Price target increased to ₹2,132 Aug 30
High number of new directors Aug 02
Astec Lifesciences Limited Appoints Burjis Godrej as an Additional, Non-Executive, Non- Independent Director Jul 26
Astec LifeSciences Limited to Report Q1, 2023 Results on Jul 25, 2022 Jul 17
Upcoming dividend of ₹1.50 per share Jul 12
Full year 2022 earnings: Revenues exceed analyst expectations Jul 06
Price target increased to ₹1,869 May 19
Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022 May 04
Full year 2022 earnings: EPS and revenues exceed analyst expectations May 04 Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022
MD & Director recently bought ₹37m worth of stock Apr 02
Astec LifeSciences Limited Announces Cessation of Ashok Hiremath as the Managing Director of the Company Apr 01
Non-Executive Non-Independent Director recently bought ₹1.5m worth of stock Mar 11
Non-Executive Non-Independent Director recently bought ₹1.5m worth of stock Mar 11
Non-Executive Non-Independent Director recently bought ₹3.5m worth of stock Mar 06
Investor sentiment deteriorated over the past week Feb 24
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Jan 26
Insider recently sold ₹1.5m worth of stock Dec 18
Investor sentiment improved over the past week Dec 13
Insider recently sold ₹2.4m worth of stock Nov 20
Price target increased to ₹1,508 Nov 16
Price target increased to ₹1,386 Aug 01
Upcoming dividend of ₹1.50 per share Jul 15
Full year 2021 earnings released: EPS ₹33.23 (vs ₹24.29 in FY 2020) Jul 06
Whole Time Director recently sold ₹2.9m worth of stock May 28
Investor sentiment improved over the past week May 24
MD & Director recently sold ₹240m worth of stock May 14
Full year 2021 earnings released: EPS ₹33.23 (vs ₹24.29 in FY 2020) May 02
Astec Lifesciences Limited Recommends Final Dividend for the Year Ended March 31, 2021, Payable on August 6, 2021 May 01
Price target decreased to ₹1,221 Apr 25
Astec LifeSciences Limited to Report Q3, 2021 Results on Jan 25, 2021 Jan 19
New 90-day high: ₹1,194 Dec 24
MD & Director recently sold ₹440m worth of stock Dec 19
New 90-day low: ₹986 Nov 18
MD & Director recently sold ₹527m worth of stock Nov 17
First half earnings released Oct 31
MD & Director recently sold ₹57m worth of stock Sep 19
MD & Director recently sold ₹15.2m worth of stock Sep 16
New 90-day high: ₹1,271 Sep 16
MD & Director recently sold ₹11.3m worth of stock Aug 24
New 90-day high - ₹1,254 Aug 20
MD & Director recently sold ₹32.9m worth of stock Aug 18
Astec LifeSciences Limited to Report Q1, 2021 Results on Jul 22, 2020 Jul 18 Shareholder Returns 533138 IN Chemicals IN Market 7D -0.4% -3.8% -4.2% 1Y -2.2% 5.4% 19.1%
See full shareholder returns
Return vs Market: 533138 underperformed the Indian Market which returned 22.5% over the past year.
Price Volatility Is 533138's price volatile compared to industry and market? 533138 volatility 533138 Average Weekly Movement 3.2% Chemicals Industry Average Movement 5.8% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: 533138 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 533138's weekly volatility (3%) has been stable over the past year.
About the Company Astec LifeSciences Limited, together with its subsidiaries, engages in the manufacture and sale of agrochemical active ingredients and pharmaceutical intermediates in India. It offers triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat; post-harvest drench; and food additive and wood preservative. The company also provides herbicides, insecticides, and specialty chemical products.
Show more Astec LifeSciences Limited Fundamentals Summary How do Astec LifeSciences's earnings and revenue compare to its market cap? 533138 fundamental statistics Market cap ₹21.18b Earnings (TTM ) -₹1.04b Revenue (TTM ) ₹3.73b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 533138 income statement (TTM ) Revenue ₹3.73b Cost of Revenue ₹3.08b Gross Profit ₹648.60m Other Expenses ₹1.68b Earnings -₹1.04b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -52.82 Gross Margin 17.39% Net Profit Margin -27.78% Debt/Equity Ratio 171.5%
How did 533138 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 05:13 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Astec LifeSciences Limited is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null Asian Markets Securities Private Limited Ankur Periwal Axis Capital Limited Satish Kumar CGS International
Show 5 more analysts 
